CO33 Risk Factors for Increased Initial Hospital Length of Stay and 30-Day Readmissions in Patients with Relapsed/Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy at an Academic Cancer Center
Abstract
Authors
P. Yeung A. Trando A.R. Jeong D. Tzachanis